New Prospects in the Treatment of Depression

  • Paul Turner


Forecasts of developments in medicine have not been particularly successful (Turner, 198l). This is because such forecasts can only be based on what is known in the present, and rely on the philosophy expressed by Bender et al (1969) — “The future must build on the present, and the present is merely a cumulative summary of the past”. However, while this may be an acceptable retrospective generalisation, it is not really a satisfying basis for a detailed predictive exercise, for while it may be possible to trace present events to their past causes, abrupt changes in the course of events may be brought about by the exercise of human intuition and ingenuity — “lateral thinking” perhaps — often associated with a considerable element of serendipity. In other words, the forecast of new prospects in anti-depressive treatment which is to follow must be based on a personal view of the importance of recent developments in psychopharmacological research. It cannot take into account abrupt changes due to momentous discoveries which may be made at any time in the future which may rapidly revolutionise our understanding of the pathogenesis of depression or approaches to its treatment.


Blood Platelet Depressive Illness Presynaptic Receptor Limbic Forebrain Monoamine Reuptake 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amer, M. S., 1977. Mechanism of action of beta-blockers in hypertension. Biochem.Pharm ac. 26:171.CrossRefGoogle Scholar
  2. Bender, A.D., Strack, A.E., Elright, G.W., Haunalter, G.V. 1969. Delphic study examines developments in medicine. Futures 1:289.CrossRefGoogle Scholar
  3. Bloom, F., 1982. Neurotransmitters and CNS disease. Lancet 2: 1382.Google Scholar
  4. Bouras, N., Bridges, P.K. 1982. Bromocriptine in depression. 8:150.PubMedCrossRefGoogle Scholar
  5. Brogden, R.N., Heel, R.C., Speight, T.M., Avery, G. S. 1979 Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 18:1.PubMedCrossRefGoogle Scholar
  6. Cowan, P.J., Grahame-Smith, D.G., Green, A.R., Heal, D.J., 1982. Beta-adrenoceptor agonists enhance 5-HT mediated behavioural responses. Br.J.Pharmac. 76:265.CrossRefGoogle Scholar
  7. Ehsanullah, R.S.B., Mulgirigama, D. L. 1979. Decreased uptake of 5-hydroxytryptamine and dopamine into blood platelets from depressed patients. Br.J.Clin.Pharmac. 7, 434P.CrossRefGoogle Scholar
  8. Frances, H., Puech, A.J., Simon, P. 1978. Psychopharmacological profiles of isoproterenol and salbutamol. J.Pharmacol. (Paris) 9,:25.Google Scholar
  9. Ghose, K., Turner, P., Coppen, A. 1975. Intravenous tyramine pressor response in depression. Lancet 2, 1317.CrossRefGoogle Scholar
  10. Ghose, K., Gifford, L., Turner, P., Leighton, M. 1976. Studies of the interactions of desmethylimipramine with tyramine in man and its correlation with the plasma concentrations. Br.J.Clin.Pharmac. 3:335.Google Scholar
  11. Grahame-Smith, D.G., Orr, M.W. 1978. Clinical psychopharmacology. in Recent advances in clinical pharmacology, ed. P. Turner, D.G. Shand. Churchill-Livingstone, Edinburgh.Google Scholar
  12. Omer, L.M.O. 1981. Placebo-controlled trial of diclofensine in the sympomatic treatment of depressive illness. Curr.Ther.Res. 29:567.Google Scholar
  13. Keller, H.M., Schaffner, R., Carruba, M.O. et al. Diclofensine — a potent inhibitor of monoamine uptake. Advs.Biochem.Psychopharmac. 31: 249.Google Scholar
  14. Langer, S. Z., 1977. Presynaptic receptors and their role in the regulation of transmitter release. Br. J. Pharmac. 60: 481.Google Scholar
  15. Lecrubier, Y., Puech, A.J., Jouvent, R., Simon, P., Widlocker, D. 1980 A beta adrenergic stimulant (salbutamol) versus clomipramine in depression: a controlled study. Br.J.Psychiat. 136:354.CrossRefGoogle Scholar
  16. Lima, D., Turner, P. 1982. Beta-blocking drugs increase responsiveness to prostacyclin in hypertensive patients. Lancet 2:444.PubMedCrossRefGoogle Scholar
  17. Middlemiss, D. N., Blakeborough, L., Leather, S. R. 1977. Direct evidence for an interaction of beta-adrenergic blockers with 5-HT receptors. Nature 267:289.CrossRefGoogle Scholar
  18. Nicholson, P.A., Turner, P. 1977. Proceedings of a symposium on nomifensine. Br.J.Clin.Pharmac. 4, 53S.Google Scholar
  19. Norman, T.R., Burrows, G.D. 1983. Clinical pharmacology of some new antidepressant Recent advances in clinical pharmacology. Vol.3. ed. P. Turner, D. G. Shand. Lecrubier, Y., Jouvent, R. D. Simon, P. Widlocker, Churchill Livingstone. Edinburgh.Google Scholar
  20. Patel, L., Turner, P. 1981. Central actions of beta-adrenoceptor blocking drugs in man. Medicin.Res.Rev. 1:387.CrossRefGoogle Scholar
  21. van Praag, H., 1982. Depression Lancet 2:1259.Google Scholar
  22. Puech, A.J., Allilaire, J.F., 1978. Experimental and clinical evidence of the antidepressant effects of a beta-adrenergic stimulant. Psychol.Med. 8:335.PubMedCrossRefGoogle Scholar
  23. Sneddon, J. M., 1973. Blood platelets as a model for monoamine containing neurones. Progr.Neurobiol. 1:151.CrossRefGoogle Scholar
  24. Souto, M., Frances, H., Lecrubier, Y., Puech, A. J., Simon, P. 1979. Antagonism by propranolol of imipramine effects in mice. Heinze, G.Eur.J.Pharmac. 60:105.CrossRefGoogle Scholar
  25. Stahl, S. M., Meltzer, H. Y. 1978. The human platelet as a model for the dopaminergic neurone. Exp.Neurol. 59,: 1.PubMedCrossRefGoogle Scholar
  26. Theohar, C., Fischer-Cornelssen, K., Brosch, H., Fischer, E.K., Petrovic, D. 1982. A comparative multicenter trial between bromocriptine and amitriptyline in the treatment of endogenous depression. Arzneim.Forsch. 32:783.Google Scholar
  27. Tuomisto, J., Tukiainen, E. 1976. Decreased uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature 262:596.PubMedCrossRefGoogle Scholar
  28. Turner, P., 1981. 1969. Delphi study of medicine.Futures 13:221.CrossRefGoogle Scholar
  29. Turner, P. 1983. Beta-adrenoceptor blocking drugs and the central nervous system in man. in Recent advances in clinical pharmacology. Vol.3 ed. P. Turner, D. G. Shand. Churchill-Livingstone. Edinburgh.Google Scholar
  30. Vetulani, J., Sulser, F. 1975. Action of various anti-depressant treatments reduces reactivity of noradrenergic cyclic AMP-generating systems in limbic forebrain. Nature 257:495.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Paul Turner
    • 1
  1. 1.Department of Clinical PharmacologySt. Bartholomew’s HospitalLondonUK

Personalised recommendations